Syncona Focuses On Creating Commercially Ambitious Businesses

With £1bn under management, patient capital company Syncona Limited reveals its strategy for creating and building companies that will generate reimbursable products for patients.

Video interview

During the 2017 BIO-Europe partnering meeting in Berlin, Germany, Syncona's Iraj Ali talks to Informa Pharma Intelligence’s Mike Ward about the investment group’s funding sweet spots.

More from Financing

More from Business